drugset / Trial / NCT05580445

Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

NCT05580445

Phase 1/2 Unknown 114 enrolled Shouyao Holdings (Beijing) Co. LTD
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the safety, tolerability, pharmacokinetics and antineoplastic activity of CT-707 in combination with toripalimab and gemcitabine in patients with advanced pancreatic cancer

Timeline

Start
2022-08-11
Primary completion
2024-08-11
Completion
2024-08-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Conteltinib Small molecule
Subject Gemcitabine Small molecule
Subject Toripalimab Monoclonal antibody

Indications